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In this review, we will highlight several studies that revolve around interleukin-8 (IL-8) and show the multiple facets that could take
in the tumor microenvironment. Chemokines that attract neutrophils (to a large extent, IL-8) can have a bimodal behavior inducing
the migration of them in the first place and later favoring the formation of NETs in the place of emission focus of the chemokine.
Also, this mechanism occurs when neutrophils migrate to tumor cells and where the extrusion of NETs in the tumor is observed. A
possible participation of NETs in cancer progression was considered; however, until now, it is difficult to decide if NETosis plays a
pro- or antitumor role, although it is necessary to emphasize that there is more experimentation focused on the protumorigenic
aspect of the NETs. The formation of NETs has a relevant role in the inhibition of the immune response against the tumor
generated by neutrophils and in turn favoring the processes involved in the development of tumor metastasis. It is striking that
we do not have more complete information about the effects of circulating chemokines on neutrophils in cancer patients and
hence the suitability of this review. No one has observed to date the impact that it could have on other cell populations to
inhibit the arrival of neutrophils and the formation/elimination of NETs. However, the extent to which NETs affect the function
of other cells of the immune system in the tumor context has not been directly demonstrated. It is necessary to identify possible
combinations of immunotherapy that involve the modulation of neutrophil activity with other strategies (immunomodulatory
antibodies or adoptive cell therapy). Therefore, knowing the mechanisms by which tumors take advantage of this ability of
neutrophils to form NETs is very important in the search for antitumor therapies and thus be able to take advantage of the
possible immunotherapeutic combinations that we currently have in clinical practice.
1. Characteristics and Effects of IL-8
Interleukin-8 (IL-8), also known as CXCL8, is a proinflam-
matory chemokine [1] of CXC type that is processed to give
rise to a functionally competent protein of 77 amino acids
in the case of IL-8 produced by parenchymal cells and
72 amino acids in the case of the one produced by mono-
cytes and macrophages. The production of IL-8 is mainly
regulated by NF-κB transcription factors and in minor
media by NF-IL6 [2]. IL-8 is a fundamental chemokine
to promote tissue infiltration by polymorphonuclear leuko-
cytes [3, 4]. This chemokine is not conserved between
species since there is no homolog in the mouse genome
that is difficult to study including their functions in
murine models genetically transformed.
The biological effects of IL-8 are exerted through two
surface receptors called CXCR1 and CXCR2 [5, 6]. These
receptors share a remarkable similarity and homology in
their sequence that suggests that they are the product of a
gene duplication. The signals from these receptors are
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transmitted through the plasma membrane through confor-
mational changes that expose regions in the intracellular
loops of the receptor. These conformational changes allow
G proteins to bind (mainly Gαi, although possibly other
G proteins insensitive to pertussis toxin are also involved)
[7]. Activation of G proteins determines the activation of
PI3Kinase, phospholipase C, and members of the RAS
family [8]. These events in turn determine the activation
of the AKT-mTOR pathway, the activation of PKC, and
the entry of ionic calcium into the cytosol [9]. The reorgani-
zation of the cytoskeleton is mainly mediated by Rho
GTPases and the FAK kinase [10] that reorganizes via ARP
2/3 the actin cytoskeleton [9]. These signaling pathways can
have effects on multiple leukocyte functions in addition to
migration [11].
The chemoattraction of neutrophils to the inflammatory
focus is mediated by different substances, among which a
family of chemokines stand out those that act on the CXCR1
and CXCR2 receptors. The signals from these receptors are
transmitted through the plasma membrane to G proteins
(mainly Gαi, although other G proteins insensitive to pertus-
sis toxin are also possibly involved). Both CXCR1 and
CXCR2 receptors do not share the same ligands. CXCR1 is
activated only in response to CXCL1, CXCL6, and CXCL8,
while CXCR2 is activated by several CXC chemokines, in
addition to the aforementioned, such as GROα, GROβ, the
neutrophil-activating peptide GPC-2, NAP-2, and ENA-78.
The exposure of these receptors to their ligands determines
the intracellular internalization and therefore the desensiti-
zation of the cell to the chemokine [12]. In addition, the
functions of CXCR1 and CXCR2 do not overlap, since the
first in addition to chemotaxis seems to play an important
role in the activation of the microbicidal capacity of poly-
morphonuclear leukocytes [13].
The expression of receptors for IL-8 in cancer cells,
endothelial cells, and tumor-associated macrophages sug-
gests that the secretion of IL-8 by cancer cells should have
an intense effect on the tumor microenvironment [9, 14].
IL-8 determines in endothelial cells proangiogenic effects
that include the proliferation, survival, and migration of
vascular endothelial cells [15]. It is also thought that IL-8
has beneficial autocrine and paracrine effects for the tumor
cells themselves [9, 14].
The effects of IL-8 in leukocyte populations of cancer
patients are not well known. It is possible that they regulate
the entry into the malignant tissue of myeloid populations.
We have shown that IL-8 attracts and retains dendritic cells
specialized in inducing T lymphocyte responses [16]. We
have also seen that IL-8 produced by xenografted human
tumors in mice determines the disorientation of the migra-
tion pattern of human dendritic cells without affecting their
immunogenic capacity [17]. It is striking that we do not
have information about the effects of circulating IL-8 on
neutrophils in cancer patients and hence the suitability of
this review.
The development of anti-IL8 humanized monoclonal
antibodies, such as ABX-IL-8, has allowed at studying the
effect of suppressing IL-8 signaling in tumor progression
[18]. Thus, it has been seen that the administration of
ABX-IL-8 to mice carrying xenografts of bladder cancer
decreases their tendency to metastasize and progress
[18], as also happens in similar models of melanoma
and prostate cancer [19]. Recently, it has been documented
that IL-8, through its proangiogenic effects, is implicated in
resistance to VEGF inhibitor drugs such as sunitinib or
bevacizumab [20].
It is important to keep in mind not only the effects of IL-8
in the tumor microenvironment, since we must not forget the
chemotactic effects on the innate response mediated by circu-
lating leukocytes against infections. It is well known that
cancer patients have a higher incidence of infections by pyo-
genic and fungal bacteria [21]. Some cases can be explained
by neutropenia secondary to myelosuppression by different
chemotherapeutic agents [22]. However, in cases with nor-
mal leukocyte levels in the peripheral blood, there is also a
marked tendency to infectious processes that are frequently
serious. It is possible that elevated levels of IL-8 disorient
the migration of polymorphonuclear leukocytes and make
it difficult for them to follow the gradient of IL-8 to migrate
to sites of acute infection [23]. If this is correct, it can be
explained that the plasma concentration of IL-8 will deter-
mine, at least, a certain propensity to develop acute infections
and/or to increase its severity and duration.
2. IL-8 Action on Polymorphonuclear Cells
The interaction of cells expressing specific receptors for a
specific chemokine with chemokine agonist determines two
molecular consequences: (1) polarization and cell migration
towards the chemokine concentration gradient and (2) inter-
nalization of specific receptors for that chemokine with the
consequent desensitization of the capacity to respond to it
[24]. In the case of IL-8, the receptors that are stimulated
and desensitized are CXCR1 and CXCR2 [11, 25].
Chronic and continued exposure of neutrophils, or other
strains of leukocytes and their myeloid hematopoietic
precursors at high concentrations of IL-8, determines the
functional desensitization of CXCR1 and CXCR2 receptors,
or at least a disorientation in their chemotactical migration
[4]. By disorientation in its migration, the high concentration
of IL-8 in the whole organism determines a disruption of the
concentration gradients that guide the chemotactic move-
ment. These phenomena can occur in the organism of
patients with advanced cancer, and it has a consequence that
peripheral polymorphonuclear leukocytes will migrate with
lower efficacy towards IL-8 gradients. Therefore, extravasa-
tion to infected/inflamed tissues will occur with less efficiency
and accordingly, susceptibility to bacterial infections and
their severity will be greater. Chemotherapy often determines
neutropenia and therefore aggravates this situation if the
migration to form pus is qualitatively altered.
An important role of IL-8 is the attraction of multiple
lymphocyte populations to the same source of emission
[26]. It is especially important in the regulation of the
immune response for tumor development and may even be
responsible in part for the suppression of this antitumor
response [27, 28].
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In this case, we have verified that IL-8 is able to attract
both DC and neutrophils to the same place, where they are
in close contact [17]. This allows a transfer of material
between the cells that subsequently can trigger an immune
response that favors tumor development.
Our experiments make evident complex relationship
between PMN and DC. Physiologically, the PMNs are much
more numerous than the DC and, therefore, could act as
possible accumulators of antigens and microbial molecules
for DC. DC can internalize the material present in the
PMN and then modulate DC functions while transferring
the antigens that PMN may carry [17]. It is within the possi-
bility that this phenomenon may occur in the same manner
by endogenous DC and could take special importance in
the immune response against the tumor. However, exactly
how relevant are these functions for the overall physiology
of the immune system still remains to be seen.
3. NET Formation and Implications
The process of NET generation, also called NETosis, is a
specific type of cell death, different from necrosis and
apoptosis [29, 30]. NETs are formed by neutrophils upon
contact with several bacteria or fungi as well as with activated
platelets or under the influence of numerous inflammatory
stimuli, and this process is associated with dramatic changes
in the morphology of the cells [31]. The main components of
NETs are DNA and granular antimicrobial proteins that
determine their antimicrobial properties. Recent studies have
shown that neutrophils are able to perform beneficial suicide
to create a sophisticated and unique microbicide network
composed of cellular content linked to the chromatic frame
[32, 33]. The pathogens strapped in these NETs are killed
by oxidative and nonoxidative mechanisms [30, 34].
Therefore, it is a powerful tool that primary serves as a
protector from severe infections, but this effective defense
tool is also a double-edged sword in the immunity [35, 36].
For this reason, overproduced NETs could provoke coagula-
tion disorders, certain autoimmune diseases, and even cancer
metastases [37].
On the other hand, several studies have discovered that
chromatin and proteases released in the circulatory system
during NET formation can regulate procoagulant and pro-
thrombotic factors [34]. In the same way, they could take part
in clot formation in blood vessels and might be cytotoxic for
tumoral cells [38]. It is speculated that NET components like
myeloperoxidase, proteinases, and histones possess antitu-
morigenic effects by means of actual killing of tumor cells.
Therefore, its main function would be to inhibit their growth,
activate the immune system, or scaffold directly tumor
cells, preventing in this way their further dissemination.
Furthermore, probably through histones, NETs can kill
activated endothelial cells thus damaging tumor-feeding
blood vessels [39, 40].
Alternatively, NETs which harbor potent proteases could
be protumorigenic by degradation of the extracellular matrix
[41]. So these structures would be able to promote extravasa-
tion and metastasis besides helping metastatic cells to evade
the immune response as by forming a barrier between cancer
cells and the immune system [42]. In this manner, NETs
could help cancer cells to escape immune recognition.
Therefore, it is important to increase the knowledge
about paths underlying NET formation and degradation
processes if we want to efficiently fight with bacterial infec-
tions and certain diseases, as in cancerous processes [29, 43].
4. Polymorphonuclear Leukocytes and NET
Production in Tumor Microenvironment
Neutrophils are the most abundant leukocyte type of the
peripheral blood and play a crucial role in the defense against
microorganisms [44]. Neutrophils are rapidly recruited to
foci of acute inflammation where their main role is to induce
the death of bacteria and fungi [45]. As we have commented
previously, the microbicidal mechanisms that neutrophils
use are mainly phagocytosis, degranulation of enzymes and
bactericidal cationic peptides, and production of free oxygen
radicals, as well as the capacity to protrude their nuclear
DNA by forming networks [46–48].
Several groups demonstrate desensitization of IL-8-
induced migration of polymorphonuclear leukocytes from
healthy individuals and cancer patients after preincubation
with IL-8, while respecting migration to other stimulus
chemistries such as E. coli bacteria irradiated with ultraviolet
light [49]. Likewise, it has been verified that the exposure to
IL-8 determines the internalization and decrease of the
surface expression of CXCR1 and CXCR2, as can be seen
by flow cytometry [49, 50]. Finally, numerous groups
confirmed the presence of high circulating levels of IL-8 in
a series of patients with advanced neoplasms [51, 52]. In this
context, elevated serum concentrations of IL-8 are observed
in patients with advanced cancer that are not observed in
healthy volunteers [51]. It is well known that the synthesis
of IL-8 is very abundant in human tumor cell lines both
in vitro and in vivo [53–55].
IL-8 for its role in attracting polymorphonuclear
leukocytes has a direct and indirect role in the stimulation
of angiogenesis [25]. Genetic studies to clarify the role of
IL-8 in cancer are complex since IL-8 is not conserved in
rodents, and, for this reason, studies in transgenic or knock-
out mice cannot be performed. In addition, studies with IL-8
in tumor xenografts are difficult to interpret because they
lack specific receptors for IL-8 in both leukocytes and endo-
thelial cells of the human tumor-carrying mouse, although
IL-8 exerts some activity on the mouse CXCR1 receptor [56].
As we have previously commented, the expression of IL-8
is frequent in human tumors and its plasma concentration in
most cases correlates directly with the tumor size [51, 52]. In
turn, we have been able to demonstrate the biological effects
of IL-8 in the repression of the antitumor immune response.
These pathogenic functions include disorientation in the
migration of dendritic cells or the attraction of suppressive
myeloid cells [49, 57]. In turn, we have shown that IL-8
induces NETs in granulocytic MDSCs in the same way that
it induces them on neutrophils [57, 58].
The role of neutrophils in the evolution of cancer is
not known in depth. Massive expression analyses using
TCGA have associated a genetic signature of the presence
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of polymorphonuclear leukocytes with an adverse progno-
sis in the development of the disease in several types of
cancer [59]. Many studies suggest that neutrophils may
acquire immunoregulatory capabilities by acquiring the
expression of molecules such as arginase-1 that inhibit
the T-lymphocyte-mediated immune response [60, 61].
In fact, a subpopulation of immature neutrophils has been
found to be abundant in cancer patients and mice, which
is called granulocytic myeloid-derived suppressor cells
(Gr-MDSC) [62].
Preliminary data have demonstrated that numerous
chemoattractant stimuli tested (CXCL1-8, LTb4, and formyl
peptides) to date are able to induce the extrusion of NETs in
neutrophils at high concentrations (Dr. A. Teijeira, personal
communication, June 15, 2018). Neutrophils are able to
polarize and migrate towards foci of tumor cells that express
these chemotactic factors in abundance [63, 64]. Upon reach-
ing the maximum production zone of the chemokine, the
gradient of chemotactic concentration disappears. It is possi-
ble that it is upon reaching a high level of receptor occupancy
when the chemotactic stimulus determines the extrusion of
the DNA and the formation of NETs [65]. By means of
intravital microscopy in tumors, previous studies observed
that neutrophils present directional motility to the tumor
and the formation of DNANETs (personal communication).
In the tumor context, these structures have been associated
mainly with processes that favor metastasis [66–68]. An
intravascular role of neutrophils is proposed, whose DNA
favors the persistence and survival of tumor cells in the
bloodstream [69, 70]. A recent study in mice also suggests
that NETs favor the invasive capacity of tumor cells favoring
their migration [71]. However, the extent to which NETs
affect the function of other cells of the immune system in
the tumor context has not been directly demonstrated.
5. IL-8 Derived from Tumors Contributes to the
Chemotactic Recruitment of
Myeloid-Derived Suppressor Cells
We have explored the relevance of the IL-8 attraction influ-
ence towards possible suppressive populations that are found
in the tumor microenvironment [57].
The suppressive myeloid cells (myeloid-derived suppres-
sor cells (MDSC)) constitute a heterogeneous population of
immature cells composed of macrophages, granulocytes,
and other populations of myeloid origin in early stages of
differentiation [72]. They especially have an important
immunosuppressive component of T cells in cancer patients,
as well as they are being able to promote the expansion of
regulatory T cells [72, 73]. Currently, the factors capable of
attracting this cellular subtype to the tumor microenviron-
ment are poorly understood. We have verified in previous
works [57] that IL-8 is a chemokine produced by cancer cells
and whose serum concentration correlates with the tumor
burden of patients and with a poor prognosis of the disease.
We have shown that IL-8 produced by cancer cells attracts
by chemotaxis to suppressive myeloid cells obtained from
the peripheral blood of patients with advanced cancer and
that this chemotactic activity can be interrupted pharmaco-
logically in tests in mice [57]. Surprisingly, it was also found
that IL-8 activates granulocytic myeloid suppressor cells to
produce the formation of extracellular neutrophil traps
(neutrophil extracellular traps (NETs)). These mechanisms
mediated by IL-8 could be relevant in the establishment of
a tumor microenvironment that favors the attraction of
leukocytes that help the tumor to evade the immune system
[74]. Definitely, IL-8 produced by tumors contributes to the
chemotactic attraction of suppressive myeloid cells and their
functional control [25, 57].
6. Importance of Work in Oncology
The development of humanized monoclonal antibodies
against CXC chemokines (such as ABX-IL-8), as well as
drugs that inhibit CXCR1/2 receptors, allowed us to study
the effect of suppressing the signaling by IL-8 or other ligands
of these receptors in the tumor progression [75–77]. Thus, it
has been seen that the administration of ABX-IL-8 to
mice carrying xenografts of bladder cancer decreases their
tendency to metastasize and progress, as it also happens
in similar models of melanoma and prostate cancer [18, 78].
A possible option in the treatment of cancer would be the
combination of effective immunotherapy strategies with
treatments that interfere with neutrophil chemoattraction
and NET extrusion [79]. Therefore, knowing the mecha-
nisms by which tumors take advantage of this ability of neu-
trophils to form NETs is important in the search for new
antitumor therapies and possible therapeutic combinations.
For this reason, it is necessary to analyze the mecha-
nism through which CXC chemokines functionally damage
human polymorphonuclear leukocytes, analyzing the corre-
lation between IL-8 and leukocyte migration parameters as
well as the propensity to severe infections in patients. It
would be possible in this way to reveal a determinant and
potentially treatable factor in the pathogenesis of the suscep-
tibility to metastasize in patients with advanced cancer.
7. Final Conclusions
We have observed the implication of IL-8 as a biomarker in
several tumors and as a chemoattractant of neutrophils and
human myeloid suppressor cells. In conclusion, there could
be a much defined axis where IL-8 plays a very important role
in the recruitment of certain lymphocyte populations and
tumor development, including the way in which tumors are
capable of developing metastasis. The influence of IL-8 is like
an actor who has different roles in the same tumor movie.
Although it is still early to unravel the true role of NETs
in the organism, it seems evident that an antimicrobial role
is something innate for PMNs as the first defense mecha-
nism. The problem lies in the particular use by certain cell
types or the exacerbation of this production that could cause
different pathologies or even favor certain metastatic events.
Future research should focus on the possibility that tumor
cells take advantage of DNA networks extruded by polymor-
phonuclear leukocytes and their immunosuppressive effect to
metastasize successfully.
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